Dysfunction of cerebral ischemic stroke
Conditions
Interventions
low dose experiment group:ABMSCs transplant, 5000000 cells each time,total three times
moderate dose experiment group:ABMSCs transplant,10000000 cells each time,total three times
high dose experiment group:ABMSCs transplant,20000000 cells each time,total three times
Sponsors
Shanghai Oriental Hospital Affiliated to Tongji University
Eligibility
Sex/Gender
All
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. The subjects were 40-65 years old, male and female; 2. Patients diagnosed with ischemic stroke within 6 ~ 24 months after stroke; 3. Moderate stroke patients with NIHSS score of 8-12; 4. Patients or their guardians agree to accept the treatment plan and sign the informed consent form; 5. Patients can cooperate with the collection and preservation of medical history data and follow-up process.
Exclusion criteria
Exclusion criteria: Any of the following conditions could not be included in the experimental group. 1. All kinds of patients with needle syncope; 2. Patients with various acute diseases; 3. Patients with severe disability and serious diseases at the end of the period; 4. Patients with severe gravity, liver and kidney dysfunction; 5. Patients with lung infection or severe infection of other organs; 6. Patients with a history of severe allergic reactions; 7. The patients who have used immunosuppressive drugs within 3 months, including steroids and vaccination history within half a year; 8. All patients with brain organic lesions that cause intracranial hypertension; 9. Patients who are or have been suffering from cancer; 10. Patients with positive serum HIV, syphilis antibody, hepatitis B, hepatitis C or other serious infectious diseases; 11. Patients with severe mental illness or disturbance of consciousness; 12. Patients with coagulation dysfunction or receiving anticoagulant therapy; 13. Patients with uncontrollable hypertension had blood pressure >= 180 / 110 mmHg after treatment; 14. Patients with severe diabetes mellitus complicated with late complications; patients with other diseases affecting limb activities (including claudication, osteoarthritis, rheumatoid arthritis, gouty arthritis, etc.) before treatment; 15. Patients who have participated in other clinical studies within 3 months; 16. Patients who have experienced surgery and trauma (including fractures) in the past month; 17. According to the judgment of the researcher, there are patients who are not suitable to participate in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety indexs;NIHSS scores; | — |
Secondary
| Measure | Time frame |
|---|---|
| Brain MRI;mRS scores;Doppler tissue imaging;Surface electromyography;Cerebrospinal fluid neurotransmitter;Cerebrospinal fluid nutritional factor; | — |
Countries
China
Contacts
Public ContactJingwen Wu
Shanghai Oriental Hospital Affiliated to Tongji University
Outcome results
None listed